Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Manny Gugliuzza who wrote (372)	4/17/1998 11:34:00 PM
From: John S. Baker	Read Replies (3) \| Respond to of 1510

<Not necessarily addressed to you, Manny> I am a relative newbie at interpreting the TA of a stock. But as I understand it, the On Balance Volume (OBV) of a stock can tell us something about what the professionals, or so-called "smart money", are doing, as distinguished from the novice (small volume) investors. If that is indeed the case, then the OBV chart for IMNR is very interesting -- link provided in a minute. It shows that the OBV rating has remained pretty much constant since early December, when the stock was at $12.80. Thus, the dip in the stock price ... while the OBV remains up there ... suggests selling by retail investors ... and thus represents a classic buying opportunity. I would sincerely appreciate hearing from any "old hands" on this thread, especially if experienced on TA, as to whether I've got this right. Thanks in advance. Now here's the link: tscn.com <FWIW, I'm long a small position in IMNR.)